The Claim
In mouse models of nonalcoholic fatty liver disease induced by a methionine/choline-deficient diet, daily intraperitoneal injection of recombinant mouse IGFBP1 at 0.015 mg/kg/day for two weeks reduces liver fat accumulation and improves markers of liver injury.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In mice with fatty liver disease caused by a specific deficient diet, daily injections of a protein called IGFBP1 for two weeks lower liver fat and improve indicators of liver damage.
See the scientific wording
In mouse models of nonalcoholic fatty liver disease induced by a methionine/choline-deficient diet, daily intraperitoneal injection of recombinant mouse IGFBP1 at 0.015 mg/kg/day for two weeks reduces liver fat accumulation and improves markers of liver injury.
A protein called IGFBP1 attaches to a receptor on liver cells called integrin β1, which turns off genes that make fat and turns on genes that burn fat. At the same time, it blocks signals that cause inflammation, leading to less fat buildup and less damage in the liver.
What the research says
1 studyIn mice with fatty liver from a bad diet, daily shots of a protein called IGFBP1 helped reduce fat in the liver and made the liver healthier, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.